Seoul, South Korea

Ho Kyung Chun

USPTO Granted Patents = 2 

Average Co-Inventor Count = 13.9

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012-2013

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ho Kyung Chun: Innovator in Cancer Research

Introduction

Ho Kyung Chun, based in Seoul, South Korea, is an accomplished inventor with a focus on cancer diagnostics and treatments. With a remarkable portfolio of two patents, he has made significant contributions to the field of cancer research, particularly regarding the FLJ25416 gene and its implications in colorectal cancer.

Latest Patents

Ho Kyung Chun’s latest patents showcase groundbreaking innovations in cancer diagnosis and treatment. The first patent addresses the use of the FLJ25416 gene, providing a composition for diagnosing cancer or screening anticancer drugs. This innovation includes an antibody directed at the protein expressed from the FLJ25416 gene and involves a kit for cancer diagnosis. The gene has shown high expression levels in specific cancer cells, and its suppression has demonstrated an inhibitory effect on cancer cell growth.

The second patent focuses on the characterization of ESM-1 as a tumor-associated marker of colorectal cancer. This invention lays the groundwork for diagnosing colorectal cancer based on the overexpression of ESM-1 in tissues or body fluids of patients. Additionally, it looks to facilitate the development of therapeutic agents for colorectal cancer.

Career Highlights

Throughout his career, Ho Kyung Chun has worked with notable organizations such as the Korea Research Institute of Bioscience and Biotechnology and St Pharm Co., Ltd. His efforts in these institutions have propelled advancements in cancer research and therapy, showcasing his commitment to innovation and improving patient outcomes.

Collaborations

Ho Kyung Chun has collaborated with esteemed colleagues, including Kyung-Sook Chung and Young Il Yeom. These partnerships have enabled him to leverage diverse expertise, fostering a collaborative environment conducive to groundbreaking discoveries in cancer treatment and diagnosis.

Conclusion

In conclusion, Ho Kyung Chun represents the forefront of innovation in cancer research. His patents not only provide new methodologies for diagnosing and treating cancer but also emphasize the significance of targeted genetic solutions in medical advancements. As he continues to explore and innovate, his contributions are likely to have a lasting impact on the field of oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…